HORIBA, one of the global leaders in a wide range of medical diagnostic equipment, and SigTuple, a medtech company that develops AI-powered digital microscopy solutions, announced today a partnership to accelerate adoption of SigTuple’s AI100 across the Indian subcontinent

Dr.Tathagato Rai Dastidar_Founder & CEO, SigTuple

Delhi, 22nd August 2022: SigTuple leverages AI & robotics, to automate the error prone and inefficient manual microscopic review of samples in laboratories. SigTuple’s AI100 is the premier solution for AI-assisted digital pathology. Its AI based cell classification is presented to a pathologist on a cloud platform, standardising the quality and increasing the efficiency of the pathologist multifold. Further, showcasing the microscopic view of the slide remotely, drives seamless transition from manual microscopy to digital microscopy and enables tele-pathology.
AI100 is complementary to HORIBA’s existing product portfolio and through this partnership, HORIBA and its affiliates will distribute AI100 across the Indian subcontinent

With a vision to replace the manual microscope in the laboratory, SigTuple’s AI100 currently automates the microscopic review of the two most common tests coming to the lab – peripheral blood smear and urine, with plans to add AI capabilities for more tests on the same platform.

It is truly an honour for us to partner with the HORIBA India team. In a very short time, HORIBA has disrupted the market and emerged as a leader in the small-midsized lab and the high-end market – covering 10,000+ customers in the region. AI100 added to HORIBA’s existing portfolio, enables a complete automation solution to be offered to all labs. This partnership is a strong vote of confidence on the SigTuple team’s efforts over the last 7 years and will go a long way in driving the adoption of AI powered digital cell morphology across the Indian subcontinent. This is also one of the first, if not the first, instance of a global medical device major getting into a distribution partnership with an Indian start-up”, stated, Dr.Tathagato Rai Dastidar - Founder & CEO, SigTuple.

Dr.Rajeev Gautam, Corporate Officer, HORIBA, Ltd., Japan President, HORIBA India Pvt. Ltd.

On the partnership, Dr. Rajeev Gautam, Corporate Officer, HORIBA Ltd., Japan & President, HORIBA India Pvt.Ltd., commented, “This strategic partnership will be built on the synergies of the complimentary nature of products that SigTuple would be offering to further strengthen the HORIBA product basket. We are glad to optimize on our market penetration and customer connect to make this partnership a success in India and global markets”.

The peripheral blood smear review is a powerful and essential diagnostic tool that provides clinicians information about a variety of diseases such as blood related cancers, anaemia, viral & bacterial infections, haematological disorders and many other life-threatening medical conditions.

Currently, 99%+ labs in the region do this manually - being completely dependent on the availability of a skilled pathologist. AI100 not only standardises the reporting quality but by enabling tele-pathology, it allows pathologists sitting in one location to look at cases across the world!

About SigTuple:

SigTuple is revolutionising pathology through robotics and advanced AI. We make the life of the pathologist easier, and thereby improve patient outcomes, by automating the inefficient and error prone manual microscopic review process for the most common tests – blood and urine microscopy. We offer a hardware + software solution. The hardware is an automated slide scanner, capable of converting any physical specimen into digital images. The AI platform analyses these images and provides clinical insights into the sample, which brings down slide review time for the pathologist, and allows her to seamlessly work remotely or collaborate with her colleagues across geographies.


HORIBA India, a subsidiary of The HORIBA Group, headquartered in Kyoto, Japan, is a world leader in analytical testing and research equipment, operating across the globe since its inception in 1953. Headquartered in New Delhi, HORIBA India started its direct operations in the country in 2006, and since then, has evolved to a company of 500+ employees with offices PAN India, factories in Haridwar in Uttarakhand, Pune and Nagpur in Maharashtra.

HORIBA India business which is evolving in the markets of Automotive, Process and Environmental instruments, Medical Diagnostics, Semiconductors and Scientific instruments has served renowned companies like Dr Lal Path Labs, SRL Diagnostics, Metropolis, Pathkind, Maruti Suzuki, Tata Motors, Mahindra, Sterlite Technologies, JSW Steel and IITs & Universities across India & SAARC to name a few, as our key patrons ensuring the best-in-class industry-standard products and high service quality.

The credit of HORIBA India’s growth goes to its dynamic and engaged employees, who are inspired by HORIBA’s culture of “JOY and FUN” to always outperform their duties. HORIBA India is desirous of continuing social development by providing state-of-the-art technological products for scientific advancement; especially for protecting health, safety, and the environment with the HORIBA vision of ‘Explore the Future’.

*Disclamier: "The pages slugged ‘Press Release’ are equivalent to advertisements and are not written and produced by Industry Outreach Magazine journalists/Editorial." We do not hold any copyrights towards the content or image. Image source: Newswire